Phase 1 Gaucher Disease Clinical Trials
3 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–3 of 3 trials
Recruiting
Phase 1Phase 2
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
Gaucher DiseaseGaucher Disease Type 1
Prevail Therapeutics15 enrolled9 locationsNCT05487599
Recruiting
Phase 1
PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)
Pompe Disease (Infantile-Onset)MPS VIIMPS I+6 more
University of California, San Francisco10 enrolled1 locationNCT04532047
Recruiting
Phase 1Phase 2
A Clinical Study Evaluating LY-M001 Injection in the Treatment of Adult Patients With Type I Gaucher Disease
Gaucher Disease Type 1
Lingyi Biotech Co., Ltd.12 enrolled3 locationsNCT06818838